fda 503a bulks list peptides bpc-157 Exciting news for coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the for use in compounding for HIMS is up nearly 8%

HIMS is up nearly 8% after FDA advisers voted to recommend adding BPC 157 to the 503A Bulks List. A major win for the peptide market. The biggest regulatory moment for peptides in 2026 happens this week. On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee meets to vote on whether BPC 157, TB 500, KPV, MOTS c, DSIP FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA Advisers Vote to Ease Restrictions on BPC 157, TB 500, and Other Novel Peptides Glitchwire FDA Advisory Committee Recommends Adding BPC 157 to Compounding List American Med Spa Association BPC 157 PASSED! Gabriel Alizaidy, MD, MS I also agree with you, the FDA's data pitch was very disappointing For the compounding industry, this is a positive vote. It does not immediately make

SKU: 41771828991 · From southroadsurgery.com.au